Up-to-date List of Hypertension Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Hypertension Medical Research Studies

RankStatusStudy
1 Recruiting Induced Hypertension for Treatment of Delayed Cerebral Ischaemia After Aneurysmal Subarachnoid Haemorrhage
Conditions: Cerebral Ischemia;   Subarachnoid Hemorrhage
Intervention: Other: Induced Hypertension
Outcome Measures: The main outcome measurement will be the modified Rankin scale at 3 months after the SAH, compared between patients who were randomized to induced Hypertension and patients who were randomized to no induced Hypertension.;   Related to treatment failure: proportion of patients in the induced Hypertension group in which induced Hypertension did not give clinical improvement of symptoms of DCI within 24 hours;   Related to the functional condition: Case fatality 30 days after SAH;   Related to the functional condition, activities of daily living (ADL), three months after the SAH assessed with the Barthel Index.;   Related to the functional condition: quality of life, three months after the SAH, estimated with the Stroke Specific Quality of Life Scale (SSQoL-12-NL).;   Related to the functional condition: anxiety and depression, three months after the SAH, assessed with the Hospital Anxiety and Depression Scale (HADS).;   Related to the functional condition: cognitive functioning, three months after the SAH, evaluated by the Cognitive Failures Questionnaire (CFQ).;   Related to adverse effects: complications related to insertion of a central venous catheter or intra-arterial catheter (including local haemorrhage and pneumothorax).;   Related to adverse effects: intracranial complications related to induced Hypertension (such as exacerbation of cerebral oedema, hemorrhagic infarction and bleeding of an asymptomatic aneurysm).;   Related to adverse effects~+mn~ • Systemic complications related to induced Hypertension (including cardiac rhythm disorders, low cardiac output state and cardiac ischemia).;   In selected centres: Related to the influence on cerebral haemodynamics: the difference in CBF, CBV, TTP and MTT between the intervention and the control groups 24-36 hours after the start of the study (i.e. CTP-2);   Related to the influence on cerebral haemodynamics: the difference in CBF, CBV, TTP and MTT between the perfusion CT-scan (at baseline, the moment of deterioration, i.e. CTP-1) and the second perfusion CT-scan (CTP-2) within the same patients.;   Direct medical costs of used health care resources and indirect, non-medical costs of lost productivity, will be compared between the two arms of the trial, twelve months after the SAH.
2 Recruiting Trans-pulmonary Biomarkers in Pulmonary Hypertension
Condition: Pulmonary Hypertension
Intervention:
Outcome Measures: Differences in Pulmonary Hypertension biomarkers in patients evaluated for Pulmonary Hypertension;   Vasodilator-induced changes in Pulmonary Vascular Resistance (PVR);   Vasodilator-induced changes in Pulmonary Hypertension biomarkers
3 Unknown  ABMSC Infusion Through Hepatic Artery in Portal Hypertension Surgery for the Treatment of Liver Cirrhosis
Conditions: Liver Cirrhosis;   Portal Hypertension;   Hepatic Decompensation;   Surgery
Interventions: Procedure: Autologous bone marrow stem cells infusion (ABMSCi) plus abdominal portal Hypertension surgery;   Procedure: open abdominal portal Hypertension surgery
Outcome Measures: Child-pugh score;   Incidence of complications;   Mortality;   blood test (hypersplenism);   liver volume calculated by CT;   Indocyanine green (ICG) retention (clearance);   blood biochemistry
4 Recruiting GAstric Bypass to Treat obEse Patients With steAdy Hypertension
Conditions: Systemic Hypertension;   Obesity
Intervention: Procedure: Laparoscopic Roux-en-Y gastric bypass (LRYGB)
Outcome Measures: reduction of Hypertension medication prescription;   reduction of Hypertension medication prescription .
5 Recruiting Registry for Pulmonary Hypertension in China
Conditions: Pulmonary Arterial Hypertension;   Chronic Thromboembolic Pulmonary Hypertension;   Death
Intervention:
Outcome Measure: Survival
6 Recruiting Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.
Conditions: Hypertension, Pregnancy Induced;   Hydralazine Adverse Reaction;   Pre-eclampsia;   Pre-eclampsia Superimposed Pre-existing Hypertension
Interventions: Drug: Labetalol;   Drug: Hydralazine
Outcome Measures: Sever persistent Hypertension;   Efficacy (Reduction in blood pressure below thresholds).;   Maternal tachycardia;   Bradycardia;   Bronchospasm;   Maternal hypotension
7 Unknown  Development and Pilot-Testing of a Patient Self Management Approach for Hypertension Using Personal Electronic Health Records
Condition: Hypertension
Intervention: Other: myBP facilitated e-health self-management
Outcome Measures: Change in Hypertension knowledge, patient self-efficacy, and patient engagement in self management activities after 3 months, in the intervention group compared to the control group;   Changes in blood pressure and antihypertensive medications
8 Unknown  Simvastatin in Patients With Isolated Arterial Hypertension
Condition: Hypertension
Intervention:
Outcome Measure:
9 Unknown  Pharmacogenomics in Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension; Pulmonary Hypertension;   PAH WHO Group I
Interventions: Drug: Sitaxsentan;   Drug: Bosentan, Ambrisentan
Outcome Measures: 6 Minute Walk Test;   Hemodynamics - Right Heart Catheterization;   Borg;   Functional Class - FC;   Toxicities;   Time of Clinical Worsening;   Decline in WHO Functional Class
10 Recruiting Auto-immunity and Pulmonary Arterial Hypertension
Conditions: Pulmonary Arterial Hypertension;   HIV Infection;   Congenital Heart Defect;   Systemic Sclerosis;   Connective Tissue Disease
Interventions: Procedure: skin biopsy;   Other: Blood Sample
Outcome Measures: Immunological markers of prognosis interest in pulmonary arterial Hypertension (PAH);   Target antigens of autoantibodies;   Subpopulations of patients with PAH whose serum is able to induce the production of reactive oxygen species (ROS)
11 Recruiting Measuring Adherence to Control Hypertension
Condition: Hypertension
Intervention: Behavioral: Electronically-measuring adherence to antihypertensive medications
Outcome Measures: Appropriateness of clinician Hypertension management;   Appropriateness of Regimen intensification;   Appropriateness of Adherence counseling;   Appropriateness of Hypertension regimen simplification
12 Recruiting Study of Personalized Dietary Intervention for the Control of Essential Hypertension
Condition: Essential Hypertension
Interventions: Other: PCFA interventional dietary counselling;   Other: conventional DASH diet counselling
Outcome Measures: a statistically significant 12 mm Hg (or more) greater change of blood pressure in one group compared to the other;   resolution of Hypertension (normal blood pressure, no drugs required);   serious (disabling) adverse events attributable to Hypertension or its drug treatment
13 Recruiting A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.
Conditions: Myeloproliferative Disease;   Pulmonary Hypertension
Intervention: Other: myeloproliferative disease
Outcome Measures: pulmonary Hypertension;   St George Respiratory Questionnaire
14 Recruiting Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension
Conditions: Pulmonary Hypertension;   Pulmonary Arterial Hypertension;   Cardiovascular Diseases;   Lung Diseases;   Tanshinone IIA Sulfonate
Interventions: Drug: 20 mg sildenafil citrate by mouth;   Drug: sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth
Outcome Measures: mPAP by right heart catheterization;   WHO functional class of pulmonary Hypertension(PH);   Borg dyspnea score;   Minnesota living with heart failure questionnaire;   6-minute walk distance (6MWD);   Pulmonary vascular resistance(PVR) measured by right heart catheterization
15 Not yet recruiting Optical Coherence Tomography (OCT) in Hypertension & Chronic Kidney Disease (CKD)
Conditions: Health;   Hypertension;   Chronic Kidney Disease
Intervention:
Outcome Measures: Choroidal & retinal morphology;   Neuro-retinal metrics
16 Unknown  Ambrisentan (Letairis) for Sarcoidosis Associated Pulmonary Hypertension
Conditions: Sarcoidosis;   Pulmonary Hypertension
Intervention: Drug: Ambrisentan
Outcome Measure: Change in 6 minute walk distance.
17 Recruiting A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
Condition: Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions: Drug: placebo;   Drug: iv sildenafil
Outcome Measures: Time on inhaled nitric oxide treatment after initiation of iv study drug;   Treatment failure rate, defined as need for additional treatment targeting persistent pulmonary Hypertension of the newborn.;   Time to final weaning of mechanical ventilation for persistent pulmonary Hypertension of the newborn;   Time from initiation of study drug to treatment failure;   Change in oxygenation parameters at 6, 12, and 24 hours from baseline;   Sildenafil plasma concentrations and corresponding PK parameters;   Safety parameters: incidence and severity of adverse events and abnormal laboratory parameters
18 Recruiting Evaluation of Pulmonary Perfusion Heterogeneity and Compliance in Patients With Pulmonary Hypertension Using Positron Emission Tomography Imaging
Condition: Pulmonary Arterial Hypertension
Intervention: Other: CT imaging, functional PET imaging
Outcome Measures: Coefficient of variation of perfusion;   Vascular compliance;   Perfusion gradient
19 Recruiting Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals
Condition: Hypertension
Intervention:
Outcome Measures: Prevalence of resistant Hypertension;   Analysis of correlation in patients with resistant Hypertension and patients with controlled Hypertension who received triple antihypertensive therapy in terms of demography, clinical characteristics and other factors
20 Unknown  Simvatstatin Used to Treat Pulmonary Hypertension
Condition: Hypertension, Pulmonary
Intervention: Drug: simvastatin
Outcome Measures: the simvastatin can alleviate pulmonary Hypertension;   pulmonary pressure;   simvastatin can highten the perioperative and long term survaval rate and the living quality

These studies may lead to new treatments and are adding insight into Hypertension etiology and treatment.

A major focus of Hypertension research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Hypertension

privacy policy